PFE - Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
2024-06-18 11:23:25 ET
Summary
- The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality."
- The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet.
- An updated analysis around Ideaya Biosciences follows in the paragraphs below.
It has been just over one year since our initial article around developmental concern Ideaya Biosciences, Inc. ( IDYA ) . The stock of this oncology focused firm has moved up 50% since that time. The shares enjoy unanimous analyst firm support currently, but the equity seems to have "topped out" a bit here so far in 2024. Just a bout of profit taking, or something more? An updated analysis follows below....
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'